IO Biotech announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board. Dr. Collins joins the IO Biotech board of directors with more than 25 years of medical experience.

She is currently the Chief Medical Officer at Enliven Therapeutics. Prior to Enliven, she served as Chief Medical Officer and Executive Vice President at Five Prime Therapeutics, where she was responsible for the strategy and execution of the company?s clinical development plans until its acquisition by Amgen in April 2021. Previously, Dr. Collins held positions of increasing responsibility at Gilead Sciences, most recently as Program and Clinical Lead for Gilead?s GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs, and Amgen, most recently as Global Lead of Oncology Biosimilars.

Dr. Collins currently serves on the board of directors for Kura Oncology. Prior to her career in the biopharma industry, Dr. Collins practiced as a medical oncologist/hematologist for 12 years. She earned her MD from Johns Hopkins University School of Medicine, completing her residency at Johns Hopkins Hospital and oncology fellowship at Stanford University School of Medicine, and her BA from Bryn Mawr College.